CA
VCYT icon

CastleArk Alternatives’s Veracyte VCYT Stock Holding History

CastleArk Alternatives’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-93,250
Closed -$4.33M – 282
2021
Q3 		$4.33M Buy
+93,250
New +$4.07M 0.17% 140

Other funds holding VCYT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CastleArk Alternatives's VCYT Position: Q4 2021 in Review

CastleArk Alternatives sold out of Veracyte (VCYT) in Q4 2021, closing a stake of 93,250 shares — an estimated $4.33M sold.

CastleArk Alternatives first reported a position in VCYT in Q3 2021 and held it in 1 quarter. The position peaked at $4.33M in Q3 2021. 217 funds tracked by Wall St. Rank hold VCYT as of Q4 2021.

  • CastleArk Alternatives reported no remaining Veracyte position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 93,250 Veracyte shares in Q4 2021, an estimated $4.33M.
  • CastleArk Alternatives first reported a position in Veracyte in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Veracyte position peaked at $4.33M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Veracyte as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.